Drugs / EXT608
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05408663 | Jul 2022 → Jun 2023 | — | Extend Biosciences Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06988670 | May 2025 → May 2027 expected | hypoparathyroidism | Extend Biosciences Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EXT608 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06988670 ↗ |
| Route | Subcutaneous | “administered via subcutaneous injection” NCT05408663 ↗ |